Search Results - "Standring, D.N."

1209 TREATMENT-EMERGENT VARIANTS FOLLOWING 3 DAYS OF MONOTHERAPY WITH IDX719, A POTENT, PAN-GENOTYPIC NS5A INHIBITOR, IN SUBJECTS INFECTED WITH HCV GENOTYPES 1–4 by McCarville, J.F, Seifer, M, Standring, D.N, Mayers, D.L

Get full text

769 A TRIPLE COMBINATION OF DIRECT-ACTING ANTIVIRAL AGENTS DEMONSTRATES ROBUST ANTI-HCV ACTIVITY IN VITRO by Lacolla, M, Lallos, L.B, Serra, I, Bilello, J.P, Soubasakos, M.A, Bonin, A, Standring, D.N

Get full text

768 IN VITRO ANTIVIRAL ACTIVITY OF IDX320, A NOVEL AND POTENT MACROCYCLIC HCV PROTEASE INHIBITOR by Lallos, L.B, Mccarville, J, Li, B, Bilello, J.P, Lacolla, M, Jakubik, J, Soubasakos, M.A, Gillum, J, Serra, I, Hubbard, L, Bonin, A, Seifer, M, Liuzzi, M, Parsy, C, Surleraux, D, Standring, D.N

Get full text

91 ANTIVIRAL ACTIVITY OF THE LIVER-TARGETED NUCLEOTIDE HCV POLYMERASE INHIBITOR IDX184 CORRELATES WITH TROUGH SERUM LEVELS OF THE NUCLEOSIDE METABOLITE IN HCV-INFECTED CHIMPANZEES by Standring, D.N, Lanford, R, Li, B, Panzo, R.J, Seifer, M, Larsson, M, Good, S.S, Zhou, X.-J

Get full text

[427] VALOPICITABINE (NM283) IS FULLY ACTIVE AGAINST KNOWN HCV PROTEASE RESISTANCE MUTATIONS IN VITRO by Bichko, V, Lallos, L, Soubasakos, M, LaColla, M, Tausek, M.M, Gillum, J, Standring, D.N

Get full text

344 PRECLINICAL PROFILES OF IDX136 AND IDX316, TWO NOVEL MACROCYCLIC HCV PROTEASE INHIBITORS by Lallos, L.B, Bilello, J.P, Soubasakos, M.A, Gillum, J, Colla, M. La, Liuzzi, M, Carville, J. Mc, Seifer, M, Good, S.S, Larsson, M, Selden, J, Parsy, C, Surleraux, D, Standring, D.N

Get full text

20 IN VITRO ACTIVITY AND PHARMACOLOGIC PROPERTIES OF TWO NOVEL SERIES OF HCV PROTEASE INHIBITORS by Standring, D.N, Parsy, C, Alexandre, F.-R, Derock, M, Leroy, F, Convard, T, La Colla, M, Lallos, L, Loi, A.-G, Musiu, C, Marceddu, T, Poddesu, B, Vargiu, L, Liuzzi, M, Surleraux, D

Get full text

67 POTENT ANTIVIRAL ACTIVITY OF SECOND GENERATION NUCLEOSIDE INHIBITORS, IDX102 AND IDX184, IN HCV-INFECTED CHIMPANZEES by Standring, D.N, Lanford, R, Cretton-Scott, E, Licklider, L, Larsson, M, Pierra, C, Gosselin, G, Perigaud, C, Surleraux, D, Mayes, B, Moussa, A, Selden, J

Get full text

588 IN VITRO ANTIVIRAL ACTIVITY AND PHARMACOLOGY OF IDX184, A NOVEL AND POTENT INHIBITOR OF HCV REPLICATION by Cretton-Scott, E, Perigaud, C, Peyrottes, S, Licklider, L, Camire, M, Larsson, M, La Colla, M, Hildebrand, E, Lallos, L, Bilello, J, McCarville, J, Seifer, M, Liuzzi, M, Pierra, C, Badaroux, E, Gosselin, G, Surleraux, D, Standring, D.N

Get full text

IDX375, A Novel Allosteric HCV Polymerase Inhibitor: In Vitro Antiviral Activity and Preclinical Profile by Dousson, C.B., Good, S.S., La Colla, M., Bilello, J., Seifer, M., Standring, D.N., Paparin, J.-L., Surleraux, D.

Get full text

514 HBV resistance determination from the telbivudine globe registration trial by Standring, D.N., Seifer, M., Patty, A., Chapron, C., Van Doorn, L.J., Chao, G., Brown, N., Lai, C.L.

Get full text

NM 283 has potent antiviral activity against genotype 1 chronic hepatitis C virus (HCV-1) infection in the chimpanzee by Standring, D.N., Lanford, R., Wright, T., Chung, R.T., Bichko, V., Cretton-Scott, E., Pan-Zhou, X., Bergelson, S., Qu, L., Tausek, M., Bridges, E., Moussa, A., Storer, R., Pierra, C., Benzaria, S., Gosselin, G., La Colla, P., Sommadossi, J.P.

Get full text